News | August 05, 2024
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Strong topline growth driven by solid performance across key brands.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Subscribe To Our Newsletter & Stay Updated
